Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Holiday spots Well known With Americans In 2024 - 2PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- 3Heart disease risk greater for women with a common condition they may not be aware they have
- 4Senegal limits foreign trips for officials as the fallout from Iran war deepens
- 5Cuba fights to contain spread of mosquito-borne chikungunya virus
- What to expect from the planets in 2026 — key dates and sky events
- Understanding the Rudiments of Tree Administrations
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- As nations push for more ambition at climate talks, chairman says they may get it
- 6 Eyewear Brands Worth Purchasing
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate
- Careful Connections: Building Association and Trust
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
